ALK and prostate carcinoma: The former device is the first device to detect prostate cancer by analyzing the expression of three exosomal biomarkers, namely prostate cancer gene 3 (PCA3), erythroblast transformation‐specific related gene (ERG), and SAM pointed domain containing ETS transcription factor (SPDEF).[145] A score of more than 15.6 indicates an increased risk of developing high‐grade prostate cancer.[145] ExoDx Lung(ALK) is another diagnostic device that has been approved to be utilized in clinics.